tbuckley/cabot-search huggingface dataset:
Preoperative Chemoradiotherapy and Postoperative Chemotherapy with Capecitabine and Oxaliplatin vs. Capecitabine Alone in Locally Advanced Rectal Cancer: Response to the Local Treatment After Chemoradiation and Surgery as Secondary Endpoint
Authors: Hans-Joachim Schmoll, Karin Haustermans, Timothy Price, Bernard Nordlinger, Ralf Hofheinz, J.-F. Daisne, J. Janssens, B. Brenner, P. Schmidt, H. Reinel, S. Hollerbach, K. Caca, F. Fauth, C.V. Hannig, John Zalcberg, Niall Tebbutt, Murielle Mauer, C. Messina, Manfred Lutz, Eric Van Cutsem
Journal: Annals of Oncology (2013)
Abstract 659: Inhibiting autophagy improves the efficacy of VN/12-1 over all-trans retinoic acid in a HER2 over-expressing SK-BR3 breast cancer xenograft model
Authors: Abhijit M. Godbole, Puranik Purushottamachar, Lalji Gediya, Vincent C.O. Njar
Journal: Cancer Research (2011)

Abstract Purpose: Autophagy is a critical physiological process of cell survival in the presence of stress and is an important cause of resistance to anti-cancer therapy. Drugs that inhibit autophagy (e.g. chloroquine) deprive the cells of this protective mechanism and therefore are promising agents in a combination therapy of breast cancer. Our group has designed and synthesized a novel retinoic acid derivative, VN/12-1. We reported previously that VN/12-1 is a potent inducer of autophagy in estrogen independent, HER2 over-expressing breast cancer cell line SK-BR3 in vitro. In the present study, we used chloroquine in combination with VN/12-1 in an SK-BR3 xenograft model to test the hypothesis that the combination of VN/12-1 and chloroquine would result in greater efficacy against SK-BR3 tumors compared to VN/12-1 alone or all-trans retinoic acid (ATRA) alone. Experimental Design: To test this hypothesis, 64 female SCID mice (8 mice per group) were inoculated with SK-BR3 cells. Once the tumors formed, the mice were treated with vehicle (control), VN/12-1 and ATRA alone or in combination with chloroquine for 30 days. The two dosages of VN/12-1 for the groups involving VN/12-1 were 2.5 mg/kg and 5 mg/kg. The doses of ATRA and chloroquine were 5 mg/kg and 50 mg/kg, respectively. All the agents were administered subcutaneously (s.c) twice a week. Results: Out of all the treatment groups, both the dosages of VN/12-1 (2.5 mg/kg and 5mg/kg) when used in combination with chloroquine were the most effective in inhibiting the growth of SK-BR3 tumors (70% and 80% growth inhibition respectively compared to vehicle control). The combination of ATRA with chloroquine did not show statistically significant inhibition of tumor growth. The effect of each treatment on the body weight and the weights of uteri was also determined. No toxicities were observed as noted by no significant changes in the weight of the mice. The data about the tumor samples’ analysis for the effect of each treatment on the expression of various tumor markers and autophagy markers and pharmacokinetic studies on VN/12-1 will be presented. Conclusion: Our studies have demonstrated for the first time that the combination of VN/12-1 and chloroquine can be used to treat estrogen independent breast cancer. It is hoped that this combination therapy would solve the problem of the development of acquired resistance due to autophagy that typically follows therapeutic treatment of breast cancer. We envision further advanced preclinical development of this combination therapy as potential therapy for breast cancer. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 659. doi:10.1158/1538-7445.AM2011-659
Abstract 1024: Therapeutic efficacy of RNA interference targeting focal adhesion kinase against orthotropic xenograft of human malignant pleural mesothelioma in SCID mice.
Authors: Jun Huang, Dai-Shun Liu, Soji Kakiuchi, Hisatsugu Goto, Masaki Hanibuchi, Yasuhiko Nishioka
Journal: Cancer Research (2013)

Abstract Malignant pleural mesothelioma (MPM) is an aggressive neop lasm of the pleura. The prognosis for MPM remains disappointing, although there have been some improvements in prognosis from newer chemotherapies and multimodality treatments. Focal adhesion kinase (FAK) is an important regulator of cellular signaling, migration, apoptosis, and cell cycle progression. We tested the hypothesis that FAK plays an important role in the pathogenesis of MPM and examined the effect of inhibiting FAK expression of MPM using small interfering RNA (siRNA) in vitro and in vivo. FAK expression was evaluated by Western and Northern blots. Knockdown of FAK resulted in detachment and proliferation inhibition of MPM cells in vitro. We assessed the therapeutic applicability of FAK siRNA in orthotopic xenograft model in SCID mice. FAK siRNA treatment inhibited the growth of MPM tumors and production of pleural effusion. These findings suggest that FAK may be a potential therapeutic target for human MPM and exogenous delivery of siRNA targeting FAK may be a useful strategy for MPM therapy. Citation Format: Jun Huang, Dai-Shun Liu, Soji Kakiuchi, Hisatsugu Goto, Masaki Hanibuchi, Yasuhiko Nishioka. Therapeutic efficacy of RNA interference targeting focal adhesion kinase against orthotropic xenograft of human malignant pleural mesothelioma in SCID mice. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1024. doi:10.1158/1538-7445.AM2013-1024
Periodontal diseases as a source of halitosis: a review of the evidence and treatment approaches for dentists and dental hygienists
Authors: Sophie De Geest, Isabelle Laleman, Wim Teughels, Christel Dekeyser, Marc Quirynen
Journal: Periodontology 2000 (2016)

Abstract Bad breath (halitosis) is an important social complaint. In most cases (≥90%), the cause of halitosis can be found within the oral cavity. Under this circumstance, the term oral malodor applies. It affects both healthy and periodontally diseased individuals. Oral malodor is mainly caused by a microbial degradation of both sulfur‐containing and nonsulfur‐containing amino acids into volatile, bad‐smelling gases. Anaerobic gram‐negative bacteria, the same species that have been linked to periodontal diseases, are especially involved in this process, explaining why clinicians often associate oral malodor with periodontitis. Some volatile organic compounds render patients more susceptible to periodontitis and this supports the malodor–periodontitis link. This review investigates the interaction between oral malodor and periodontal diseases. Pro and con arguments regarding the mechanisms of halitosis and clinical implications will be presented. In general, however, the impact of tongue coatings has been found to be the dominant factor, besides gingivitis and periodontitis. The last part of this review discusses the treatment of bad breath, with different options.
Oncology Nursing: Major Changes Needed to Meet Changing U.S. Health Care Needs
Authors: C. Nelson
Journal: JNCI Journal of the National Cancer Institute (1995)

Journal Article Oncology Nursing: Major Changes Needed to Meet Changing U.S. Health Care Needs Get access Corinna Nelson Corinna Nelson Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 87, Issue 1, 4 January 1995, Pages 6–9, https://doi.org/10.1093/jnci/87.1.6 Published: 04 January 1995
FRI0261 B cell stimulating cytokines baff, IL-21 and IL-33 mrna expression are elevated coordinately in active rnp autoantibody+ sle
Authors: E. L. Greidinger, J. Pignac-Kobinger, A. C. Garza Romero, N. B. Perumal, V. Kondragunta, R. W. Hoffman
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> We examined a cohort of 79 consecutive patients classified as anti-ribonuclear protein (anti-RNP)+ systemic lupus erythematosus (SLE). All patients provided RNA samples obtained after providing informed consent. There were 73 female and 6 male subjects. Disease duration ranged from 0 to 453 months with a median of 37.5 months. SLE Disease Activity Index (SLEDAI) ranged from 0 to 31 with a median of 6. The goal of this study was to characterize gene expression profiles in active and inactive RNP autoantibody+ SLE versus healthy blood donors. <h3>Methods</h3> Gene expression profiling was performed using Affymetrix microarrays on 79 patients and 30 healthy blood donors. mRNA from the 109 samples passed quality control and were analyzed using Affymetrix U133 Plus 2.0 expression arrays to determine gene expression, and data were compared after normalization using Robust Multichip Average algorithm. Statistical analyses were performed using two-sample t-test or univariate regression analysis. <h3>Results</h3> BAFF, IL-21, IL-33, and CXCL13 mRNA expression was significantly higher in patients versus healthy controls (p&lt;2E-8) while ICOS and CXCR5 were lower in patients (p&lt;3.7E-18). There were strong correlations between expression of these genes, especially in patients with more active disease as defined by SLEDAI of 6 or greater. BAFF, IL-21, IL-33, and CXCL13 were high in patients with active disease. In addition, several of these were coordinately regulated. We found correlation for BAFF vs ICOS (p&lt;0.02); BAFF vs CXCR5 (p&lt;0.02); IL-21 vs ICOS (p&lt;0.0001); IL-21 vs CXCR5 (p&lt;0.0001) and IL-33 vs ICOS (p&lt;0.02). <h3>Conclusions</h3> There was elevation of mRNA expression for the B cell stimulatory cytokines BAFF, IL-21 and IL-33 in active RNP+ SLE supporting the concept that these are potentially important therapeutic targets for treatment of SLE in the presence of autoantibodies. In addition, the observed differences of mRNA expression of factors influencing B cell migration and trafficking, ICOS and CXCL13-CXCR5, and the apparent coordinate change of these with other B cell stimulator cytokines (BAFF, IL-21 and IL-33) in active SLE suggests that these may also be of importance in disease pathogenesis. <b>Disclosure of Interest</b>: E. Greidinger Consultant for: Eli Lilly &amp; Company, J. Pignac-Kobinger: None Declared, A. Garza Romero: None Declared, N. Perumal Shareholder of: Eli Lilly &amp; Company, Employee of: Eli Lilly &amp; Company, V. Kondragunta Shareholder of: Eli Lilly &amp; Company, Employee of: Eli Lilly &amp; Company, R. Hoffman Shareholder of: Eli Lilly &amp; Company, Employee of: Eli Lilly &amp; Company
Abstract 1540: MAPK signaling profiles differ between 1,25D-sensitive HL60G and 1,25D-resistant 40AF human leukemia cells
Authors: Xiangwen Chen-Deutsch, George P. Studzinski
Journal: Cancer Research (2010)

Abstract The resistance to 1,25-dihydroxyvitamin D3 (1,25D) could be an obstacle for potential clinical use of vitamin D in differentiation therapy of leukemia. 40AF cells are a subline of HL60 cells and provide a model for studies of 1,25D-resistance. It is known that 40AF cells grow more rapidly than the parental cells, and have a high percentage of cells in S phase. Also, the addition of the plant antioxidant carnosic acid and a kinase inhibitor SB202190 (the combination dubbed DCS) can partially overcome the resistance to 1,25D. To better understand the basis for this resistance we examined MAPK network profiles, previously shown to be important for HL60 cell differentiation, on mRNA level by RT2-PCR arrays. The results showed that 17 out of 84 genes studied had significantly altered mRNA levels (more than 2 fold) in 40AF cells compared to HL60G cells. Eighteen genes had lower basal level of expression in 40AF compared to HL60G cells, and after partial reversal of resistance by DCS treatment these genes showed increased expression; in contrast, 20 genes had higher basal levels in 40AF cells and their expression was decreased by DCS, suggesting that these genes may be involved in 1,25D resistance. Also, DCS treatment of 40AF cells changed the expression of the RAS-ERK pathway components more obviously than the JNK and the p38MAPK pathways. Mitotic cyclins and CDKs had a generally enhanced expression in 40AF cells compared to HL60G, and their expression decreased following DCS treatment, consistent with the slow down of the cell cycle by DCS, perhaps also because several CKIs, including p21Cip1, dramatically increased. Studies using Phospho-MAPK arrays showed that treatment of both HL60G and 40AF cells with 1,25D or DCS altered the levels of phosphorylated proteins of MAPK family members P-ERK2 in the ERK pathway, P-JNK2 in the JNK pathway, P-p38 alpha/delta/gamma in the p38 pathway, P-Akt1 in the PI3/Akt pathway. The gene expression studies will be validated by Westerns, and MAPK activity by kinase assays. In summary, MAPK signaling networks may play important roles in 1,25D resistance in AML cells, and modification of network expression can influence cell cycle progression and cell differentiation to partially reverse the resistance to 1,25D of non-responding leukemia cells. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 1540.
SAT0591-HPR Follow-Up Interventions Improved Long-Term Physical Function in Patients with Rheumatic Diseases: Results from A Systematic Review
Authors: G. Berdal, G. Smedslund, H.S. Dagfinrud, K.B. Hagen, I. Kjeken
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Although supportive follow-up has been implemented in a variety of treatment practices and is recommended by clinical guidelines, little is known about the unique effects on clinical outcomes in patients with rheumatic diseases. <h3>Objectives</h3> To describe the design and determine the clinical effects of follow-up interventions delivered after or alongside non-surgical treatment or rehabilitation of patients with rheumatic diseases. <h3>Methods</h3> We performed a systematic review of randomized controlled trials searching the Ovid Medline, Embase, Cinahl, AMED, PsychINFO and Cochrane Library databases up to February 2013. Trials evaluating the additional effects of interventions designed to enhance and/or prolong the effects of treatment or rehabilitation for patients with rheumatic diseases were included. Risk of bias was assessed by two independent reviewers. Data on pain, depression and physical function were pooled in separate meta-analyses, including analyses to calculate short-term (0-2 months) and long-term (5-6 months after follow-up intervention) effects. The GRADE (Grading of Recommendation Assessment Development and Evaluation) approach was used to judge the quality of the evidence. <h3>Results</h3> The searches generated 3231 citations, of which 11 original trials were included. The results demonstrated a great variety in the design of follow-up interventions, with telephone support as the most frequent mode of delivery. We found moderate quality evidence for small effects of follow-up on self-reported physical function, with standardized mean differences of -0.15 (95% confidence interval (95% CI) -0.31, 0.01, p=0.07) at short term, and -0.21 (95% CI) -0.40, -0.03, p=0.03) at long-term. Moderate quality evidence showed no effect of follow-up interventions on short-term depression. Low quality evidence showed no significant effects on short-term pain, and very low quality evidence showed no significant effects on long-term pain and depression. <h3>Conclusions</h3> Currently, there is no clear evidence concerning what constitutes an optimal design of follow-up interventions. No significant positive effects of follow-up interventions were found for pain and depression. There is evidence that follow-up interventions are effective in improving long-term physical function in patients with rheumatic diseases. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.3772
FRI0228 High Prevalence of Enthesitis in Patients with Systemic Sclerosis Demonstrated by Doppler Ultrasonography: Table 1
Authors: E. Kiliç, G. Kilic, O. Akgul, S. Ozgocmen
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Systemic sclerosis (SSc) is a chronic, autoimmune and progressive connective tissue disease characterized by widespread vascular and fibrotic changes in the skin and internal organs. Musculoskeletal involvement is frequent in patients with SSc and may be the presenting manifestation of the disease which may also causes significant functional disability. Enthesitis is characteristic feature of spondyloarthritis including ankylosing spondylitis and psoriatic arthritis however the prevalence and clinical relevance of enthesitis is not known in patients with SSc. <h3>Objectives</h3> The aim of this study was to investigate the presence of enthesitis in patients with SSc by using Doppler ultrasonography. <h3>Methods</h3> Patients met 2013 ACR/EULAR classification criteria for SSc were included. All patients were female. Patients and age-matched healthy women underwent ultrasonographic examination using Logic P5 (GE Medical Systems, UK) with a linear probe (7–12 MHz). The Madrid Sonography Enthesitis Index (MASEI) was used to score 6 entheses sites. <h3>Results</h3> We evaluated 6 entheses in 40 patients with SSc (mean age 48±12.8 years) and 40 healthy controls (49.3±9.3 years). Mean disease duration and diagnostic delay was 10.1 and 6.0 years, respectively. In SSc group, there was 20 (50%) diffuse cutaneous SSc, 16 (40%) limited cutaneous SSc, 2 (2.5%) sine SSc and 2 (2.5%) overlap syndromes. Demographic and clinical features were similar between dcSSc and lcSSc. Patients had higher mean MASEI score compared to controls (16.1±9.7 vs 2.0±2.3, p&lt;0.0001). Thickness of the triceps, quadriceps, Achilles tendons as well as proximal and distal patellar ligaments were higher in patients compared to controls. MASEI scores correlated positively with age (r:0.29, p:0.008), modified Rodnan skin score (r:0.49, p:0.002), pulmonary involvement grade (r:0.35, p:0.037) and inversely with hand grip strength (r:-0.48, p:0.004). Thickness of left plantar aponeurosis positively correlated with age (r:0.28, p:0.012) and BMI (r:0.24, p:0.032). Doppler sonographic features of the entheses are presented in Table 1. <h3>Conclusions</h3> To the best of our knowledge this is the first study showing the high prevalence of enthesitis in patients with SSc assessed by Doppler ultrasonography. Enthesitis is an important musculoskeletal manifestation in patients with SSc and could be identified by using Doppler ultrasonography. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.4937
Pan-genome multilocus sequence typing and outbreak-specific reference-based single nucleotide polymorphism analysis to resolve two concurrent Staphylococcus aureus outbreaks in neonatal services
Authors: S. Roisin, C. Gaudin, R. De Mendonça, J. Bellon, K. Van Vaerenbergh, K. De Bruyne, B. Byl, H. Pouseele, O. Denis, P. Supply
Journal: Clinical Microbiology and Infection (2016)
Integrated genome-scale analysis of the transcriptional regulatory landscape in a blood stem/progenitor cell model
Authors: Nicola K. Wilson, Stefan Schoenfelder, Rebecca Hannah, Manuel Sánchez Castillo, Judith Schütte, Vasileios Ladopoulos, Joanna Mitchelmore, Debbie K. Goode, Fernando J. Calero-Nieto, Victoria Moignard, Adam C. Wilkinson, Isabel Jimenez-Madrid, Sarah Kinston, Mikhail Spivakov, Peter Fraser, Berthold Göttgens
Journal: Blood (2016)
Abstract P4-09-02: Prognostic and Predictive Value of Centrally Reviewed Ki67 Labeling Index in Postmenopausal Women with Endocrine-Responsive Breast Cancer: Results from Austrian Breast and Colorectal Cancer Study Group Trial 8
Authors: Z Bago-Horvath, M Rudas, R Jakesz, P Dubsky, CF Singer, O Dietze, R Greil, A Jelen, F Offner, A Lang, C Gruber, S Pöstlberger, MFX Gnant, M. Filipits
Journal: Cancer Research (2010)

Abstract Purpose: The aim of the present study was to assess the prognostic and predictive value of Ki67 labeling index in postmenopausal hormone receptor-positive early breast cancer patients who were treated with adjuvant tamoxifen or anastrozole after tamoxifen. Patients and Methods: We determined the expression of Ki67 by immunohistochemistry on whole tissue sections of breast carcinoma patients who had been enrolled in Austrian Breast and Colorectal Cancer Study Group (ABCSG) Trial 8 and received tamoxifen for 5 years or tamoxifen for 2 years followed by anastrozole for 3 years. Ki67 labeling index was evaluated as continuous variable or dichotomized at 10%. Distant recurrence and death were analyzed using Cox models adjusted for clinical and pathological factors. Results: High Ki67 labeling index was observed in 394 of 1587 (23%) tumors and was associated with poor outcome. Patients with high Ki67 labeling index had a significantly shorter distant recurrence-free survival (adjusted hazard ratio [HR] for distant recurrence 2.16, 95% confidence interval [CI] 1.43-3.25, P &amp;lt; 0.001) and overall survival (adjusted HR for death 1.77, 95% CI 1.30-2.42, P &amp;lt; 0.001) as compared to patients with low Ki67 labeling index. No interaction between Ki67 labeling index and treatment was observed (P = 0.84). Conclusion: High Ki67 labeling index is an independent poor prognostic factor for distant recurrence and death in postmenopausal women with early-stage, hormone receptor-positive breast cancer but is not predictive for outcome of adjuvant treatment with either tamoxifen or tamoxifen followed by anastrozole. Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P4-09-02.
ASSESSMENT OF MISSING LINKS IN ATHEROGENESIS: PILOT STUDY OF GREAT APES AND HUMANS
Authors: Randall C. Thompson, L. Wann, Navneet Narula, Jagat Narula, M. Linda Sutherland, James Sutherland, Adel Allam, Christine France, Bruno Frohlich
Journal: Journal of the American College of Cardiology (2016)
LOCAL DELIVERY OF BISPHOSPHONATES RESULTS IN AN ATTENUATION OF CALCIFICATION IN AN EXPERIMENTAL MODEL OF AORTIC STENOSIS
Authors: Andreas Synetos, Konstantinos Toutouzas, Maria Drakopoulou, Georgios Benetos, Giorgos Peskesis, George Agrogiannis, George Latsios, Apostolos Papalois, Angelos Papanikolaou, Eleftherios Tsiamis, Dimitris Tousoulis
Journal: Journal of the American College of Cardiology (2016)